期刊文献+

厄贝沙坦不同时间用药对血压昼夜节律的影响研究 被引量:6

The Pharmaco-chronological Effects of Irbesartan on Day-night Rhythm of Blood Pressure in Hypertensive Patients
下载PDF
导出
摘要 目的按照时间药物学的原则,探讨不同用药时间服用厄贝沙坦对非杓型高血压患者血压昼夜节律的影响。方法采用动态血压检测的方法筛选出83例非杓型高血压患者,随机分为厄贝沙坦晨起服药组(41例)和晚上服药组(42例),均给以厄贝沙坦150~300mg口服,1次/d,共治疗24周。药物治疗前后分别进行诊室血压和动态血压监测的检查。结果两组的诊室收缩压(SBP)在治疗后均明显降低,两组的诊室收缩压(SBP)在治疗前后差异无统计学意义(P>0.05)。动态血压结果显示,两组均能降低夜间SBP(P<0.05,P<0.01),夜间服药更能有效地降低夜间的SBP。晨起服药组的白天血压达标率(SBP<135mmHg)为36.5%,晚上服药组的白天血压达标率为33.3%,差异无统计学意义(P>0.05)。晨起服药组的夜间血压达标率(SBP<125mmHg)为29.2%,晚上服药组的夜间血压达标率为61.9%,差异有显著意义(P<0.01)。晨起服药组血压昼夜节律纠正率为19.5%,晚上服药组血压昼夜节律纠正率为52.4%,差异有显著意义(P<0.01)。结论对于非杓型高血压患者,厄贝沙坦晚上服药可以有效地纠正夜间的高负荷血压,提高夜间血压达标率,改善血压昼夜节律。 Objective To investigate the pharmaco-chronological effects of irbesartan on day-night rhythm of blood pressure in non-dipper hypertensive patients.Methods Eighty-three non-dipper hypertensive patients were divided into two classes:morning dose(n=41) and evening dose program(n=42).All patients were treated with irbesartan(150~300mg/d) for 24 weeks.Results Both programs decreased office SBP with no differences between them.ABPM showed that both programs effectively decreased night SBP,while evening program reduced night SBP more pronouncedly.Although The target day-time SBP(135 mmHg) was of no differences between the two programs(36.5% vs 33.3%,P0.05),the target night-time SBP(125 mmHg) was achieved by evening program in52.4% patients which was greatly higher than that by morning program(29.2%,P0.01).Circadian rhythm transformed from non-dipper to dipper was found in 19.5% in morning program versus 52.4% in the evening program(P0.01).Conclusion The evening programs of irbesartan administration were effective in decreasing night BP and improving day-night rhythm of blood pressure.
出处 《实用心脑肺血管病杂志》 2011年第11期1844-1845,1848,共3页 Practical Journal of Cardiac Cerebral Pneumal and Vascular Disease
关键词 厄贝沙坦 时间治疗学 非杓型血压 Irbesartan Chronotherapy Non-dipper hypertensive
  • 相关文献

参考文献6

二级参考文献18

  • 1任常陵.血压的日内变动和降压药的使用方法[J].日本医学介绍,2005,26(1):27-28. 被引量:7
  • 2Greenland P,Abrams J,Aurigemma GP,et al.Preventoin Conference V:Beyond secondary prevention:Identifying the high-risk patient for primary prevention:Noninvasive tests of atheroselerotic burden:Writing Group Ⅲ[J].Circulation,2000,101(1):16-22.
  • 3Resnick HE,Lindsay RS,McDermott MM,et al.Relationship of high and low ankle-brachial index to all-cause and cardiovascular disease mortality:The Strong Heart Study[J].Circulation,2004,109(6):733-739.
  • 4Duprez D.Hope brings hope for the use of the ankle-brachial index as cardiovascular risk marker[J].Eur Heart J,2004,25(1):1-2.
  • 5Newman AB,shemanski L,Manolio TA,et al.Aankle-arm index as a predictor of cardiovascular disease and mortality in the Cardiovascular Health Study.The Cardiovascular Health Study Group[J].Arteriosclar Thromb Vasc Biol,1999,19(3):538-545.
  • 6Sikkink CJ,Van Asten WN,Van Hof MA,et al.Decreased ankle-brachial indices in relation to morbidity and mortality in patients with peripheral arterial disease[J].Vasc Med,1997,2(3):169-173.c.
  • 7Hooi JD,Kester ADK,Stoffers HKJH,et al.A symptomatic peripheral arterial occlusive disease predicted cardiovascular morbidity and mortality in a 7-year follow-up study[J].J Clin Epidemiol,2004,57(3):294-300.
  • 8张麟,中华心血管病杂志,1994年,22卷,178页
  • 9张维忠,上海医学,1992年,15卷,520页
  • 10Waeber B. A review of irbesartan in antihypertensive therapy:comparison with other antihypertensive agents[J]. Current Therapeutic Research, 2001,62:505-21.

共引文献2887

同被引文献87

引证文献6

二级引证文献44

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部